Investigational Drug Information for Deoxythymidine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Deoxythymidine?
Deoxythymidine is an investigational drug.
There have been 10 clinical trials for Deoxythymidine.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.
The most common disease conditions in clinical trials are HIV Infections, Infections, and Infection. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Zogenix, Inc., and Modis Therapeutics, Inc.
There are two hundred and twenty-three US patents protecting this investigational drug and twenty-nine international patents.
Summary for Deoxythymidine
| US Patents | 223 |
| International Patents | 29,843 |
| US Patent Applications | 4,228 |
| WIPO Patent Applications | 2,808 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2021-11-01) |
| Vendors | 89 |
Recent Clinical Trials for Deoxythymidine
| Title | Sponsor | Phase |
|---|---|---|
| Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) | Zogenix, Inc. | Phase 3 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) | Modis Therapeutics, Inc. | Phase 3 |
Clinical Trial Summary for Deoxythymidine
Top disease conditions for Deoxythymidine
Top clinical trial sponsors for Deoxythymidine
US Patents for Deoxythymidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Deoxythymidine | See Plans and Pricing | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | See Plans and Pricing |
| Deoxythymidine | See Plans and Pricing | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | Axovant Sciences GmbH (Basel, CH) | See Plans and Pricing |
| Deoxythymidine | See Plans and Pricing | Urethane-crosslinked biodegradable elastomers | Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA) Biocant-Center of Innovation and Biotechnology (Cantanhede, PT) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Deoxythymidine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Deoxythymidine | Canada | CA2739250 | 2028-10-01 | See Plans and Pricing |
| Deoxythymidine | Canada | CA2813743 | 2028-10-01 | See Plans and Pricing |
| Deoxythymidine | Canada | CA2993404 | 2028-10-01 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
